NCT06680323 Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young Adults
| NCT ID | NCT06680323 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Tuebingen |
| Condition | Melanoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2025-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-01-01 with a primary completion date of 2025-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this study is the identification of environmental and genetic factors involved in the risk and progression of melanoma in children, adolescents and young adults (CAYA). The secondary objectives are to generate a model integrating the genetic and environmental factors to estimate the risk of developing melanoma and improve the primary prevention of melanoma through evidence-based interpretation of environmental risk.
Eligibility Criteria
Inclusion Criteria: * confirmed melanoma * age until 30 years old Exclusion Criteria: * no available biological material * no signed informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06680323 clinical trial?
This trial is open to participants of all sexes, up to 30 Years, studying Melanoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06680323 currently recruiting?
Yes, NCT06680323 is actively recruiting participants. Contact the research team at ines.brecht@med.uni-tuebingen.de for enrollment information.
Where is the NCT06680323 trial being conducted?
This trial is being conducted at Düsseldorf, Germany, Florence, Italy, Milan, Italy, Gdansk, Poland and 2 additional locations.
Who is sponsoring the NCT06680323 clinical trial?
NCT06680323 is sponsored by University Hospital Tuebingen. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.